[Click e-Stock] "Ildong Pharmaceutical Shows Positive GLP-1 Clinical Results... Comparable to Eli Lilly"

Ivy Research analyzed on July 24 that Ildong Pharmaceutical is showing favorable clinical data for its oral GLP-1 new drug and is also in discussions for a licensing deal with global obesity drug developer Company N. The firm did not provide an investment opinion or target price.

Ivy Research stated, "The pipeline that provides the greatest upside to Ildong Pharmaceutical's corporate value is the oral GLP-1 new drug 'ID110521156.' Ildong Pharmaceutical began developing this small-molecule oral GLP-1 new drug in 2023, and has confirmed competitive interim results through single ascending dose (SAD) and multiple ascending dose (MAD) studies in domestic Phase 1 clinical trials."

The firm continued, "According to the disclosed clinical data, the average weight loss rate was -5.50% at the low dose (50mg) and -6.89% at the medium dose (100mg), with a maximum of -11.9%. No hepatotoxic side effects were observed, and there were no reported cases of clinical discontinuation due to gastrointestinal side effects." The firm further emphasized, "These results are comparable to the data for Orfoglipron by Eli Lilly, which is the leading candidate in the small-molecule GLP-1 field."

Ivy Research added, "This clinical trial was designed with consultation from global obesity drug developer Company N," and stated, "Discussions for a licensing deal are also underway."